BioSpace News Archive

Raydiant Oximetry, Inc., a clinical-stage medical device company that develops medical technologies to improve outcomes for mothers and babies during childbirth, announced that it has oversubscribed a $7.5 million Series A3 extension round.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the addition of a new Universal Plus Panel to its Foresight® Carrier Screen.

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), held in Boston, MA, June 1-4, 2024.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”) today announced it has been honored with an invitation to apply for a prestigious grant from the ALS Association head by James Berry, MD, MPH and Suma Babu, MBBS, MS, the Director and Co-Director of the Neurological Clinical Research Institute (NCRI) at Mass General Hospital, a founding member of Mass General Brigham.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BE-101, a novel engineered B Cell medicine (BCM) being developed for the treatment of Hemophilia B.

Omeros Corporation announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, June 6, 2024, starting at 10:00 a.m. Pacific Time.

Champions Oncology, Inc., a leader in the development of advanced preclinical oncology solutions, has announced a strategic partnership with Medicines Discovery Catapult, enhancing their combined capabilities in the expanding field of radiopharmaceutical therapeutics.

NanoImaging Services and Cube Biotech have announced a partnership agreement to develop a streamlined, cryo-EM enabled gene-to-structure workflow, to ultimately accelerate medicinal chemistry analysis and revolutionize the field of membrane protein research.

Awakn Life Sciences Corp.is pleased to announce that, further to its press releases dated April 3, 2024, and April 17, 2024, it has closed a second tranche (the “Second Tranche”) of its previously announced non-brokered private placement (the “Offering”) through the issuance of an additional 857,142 units (the “Units”) at a price of $0.46 per Unit for additional gross proceeds of $394,285.

ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company.